Postradioiodine Graves' management: The PRAGMA study
Petros Perros,Ansu Basu,Kristien Boelaert,Colin Dayan,Bijay Vaidya,Graham R Williams,John H Lazarus,Janis Hickey,William M Drake,Anna Crown,Stephen M Orme,Andrew Johnson,David W Ray,Graham P Leese,Thomas Hugh Jones,Prakash Abraham,Ashley Grossman,Aled Rees,Salman Razvi,Fraser W Gibb,Carla Moran,Asgar Madathil,Miloš P Žarković,Zoe Plummer,Sheba Jarvis,Agnieszka Falinska,Anand Velusamy,Violet Sanderson,Nadia Pariani,Stephen L Atkin,Akheel A Syed,Thozhukat Sathyapalan,Sath Nag,Jackie Gilbert,Helena Gleeson,Miles J Levy,Colin Johnston,Nigel Sturrock,Stuart Bennett,Biswa Mishra,Isha Malik,Niki Karavitaki
DOI: https://doi.org/10.1111/cen.14719
Abstract:Objective: Thyroid status in the months following radioiodine (RI) treatment for Graves' disease can be unstable. Our objective was to quantify frequency of abnormal thyroid function post-RI and compare effectiveness of common management strategies. Design: Retrospective, multicentre and observational study. Patients: Adult patients with Graves' disease treated with RI with 12 months' follow-up. Measurements: Euthyroidism was defined as both serum thyrotropin (thyroid-stimulating hormone [TSH]) and free thyroxine (FT4) within their reference ranges or, when only one was available, it was within its reference range; hypothyroidism as TSH ≥ 10 mU/L, or subnormal FT4 regardless of TSH; hyperthyroidism as TSH below and FT4 above their reference ranges; dysthyroidism as the sum of hypo- and hyperthyroidism; subclinical hypothyroidism as normal FT4 and TSH between the upper limit of normal and <10 mU/L; and subclinical hyperthyroidism as low TSH and normal FT4. Results: Of 812 patients studied post-RI, hypothyroidism occurred in 80.7% and hyperthyroidism in 48.6% of patients. Three principal post-RI management strategies were employed: (a) antithyroid drugs alone, (b) levothyroxine alone, and (c) combination of the two. Differences among these were small. Adherence to national guidelines regarding monitoring thyroid function in the first 6 months was low (21.4%-28.7%). No negative outcomes (new-onset/exacerbation of Graves' orbitopathy, weight gain, and cardiovascular events) were associated with dysthyroidism. There were significant differences in demographics, clinical practice, and thyroid status postradioiodine between centres. Conclusions: Dysthyroidism in the 12 months post-RI was common. Differences between post-RI strategies were small, suggesting these interventions alone are unlikely to address the high frequency of dysthyroidism.